AVAH
Aveanna Healthcare Holdings Inc
$
8.740
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.875
Open
8.300
VWAP
8.70
Vol
977.39K
Mkt Cap
1.83B
Low
8.275
Amount
8.51M
EV/EBITDA(TTM)
12.84
Total Shares
192.38M
EV
3.15B
EV/OCF(TTM)
35.15
P/S(TTM)
0.79
Aveanna Healthcare Holdings Inc. is a provider of diversified home care platforms. Its segments include Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). PDS segment includes private duty nursing (PDN) services, as well as pediatric therapy services. HHH segment includes home health services, as well as hospice and specialty program services. Its home health services involve the provision of in-home services to its patients by its clinicians, which include nurses, therapists, social workers and home health aides. Its hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Medical Solutions segment offers a line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. It also provides case management services to assist families and patients by coordinating the provision of services between insurers and other healthcare providers.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
631.43M
+7.1%
0.147
-18.46%
612.02M
+9.44%
0.131
+30.5%
622.03M
+19.65%
0.126
+152.2%
Estimates Revision
The market is revising No Change the revenue expectations for Aveanna Healthcare Holdings Inc. (AVAH) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 17.00%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+3.27%
In Past 3 Month
Stock Price
Go Up
+17.00%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast AVAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVAH is 10.06 USD with a low forecast of 9.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.740
Low
9.00
Averages
10.06
High
12.50
Current: 8.740
Low
9.00
Averages
10.06
High
12.50
BMO Capital
Outperform
initiated
$11
2025-11-12
Reason
BMO Capital
Price Target
$11
2025-11-12
initiated
Outperform
Reason
BMO Capital initiated coverage of Aveanna with an Outperform rating and $11 price target. Shares are up about 130% since early August on strong Q2 and Q3 results fueled by state reimbursement increases, preferred payer expansion, and disciplined cost control, which also lowered leverage, the analyst tells investors in a research note. While future Medicaid rate hikes may be limited, ongoing payer conversions, cost discipline, and potential M&A underpin expectations for 10+ long-term EBITDA growth, the firm says.
UBS
AJ Rice
Neutral
maintain
$9
2025-11-07
Reason
UBS
AJ Rice
Price Target
$9
2025-11-07
maintain
Neutral
Reason
UBS analyst AJ Rice raised the firm's price target on Aveanna to $9.50 from $9 and keeps a Neutral rating on the shares.
Jefferies
Buy
maintain
$11
2025-10-28
Reason
Jefferies
Price Target
$11
2025-10-28
maintain
Buy
Reason
Jefferies raised the firm's price target on Aveanna to $12.50 from $11 and keeps a Buy rating on the shares after the company announced a secondary offering of 10M shares along with preliminary Q3 results last week. The preliminary results reflect management's success in securing favorable reimbursement, driving volume and EBITDA growth, the analyst tells investors.
RBC Capital
Ben Hendrix
Sector Perform
maintain
$8 -> $10
2025-10-23
Reason
RBC Capital
Ben Hendrix
Price Target
$8 -> $10
2025-10-23
maintain
Sector Perform
Reason
RBC Capital analyst Ben Hendrix raised the firm's price target on Aveanna to $10 from $8 and keeps a Sector Perform rating on the shares. The company reported strong preliminary Q3 results that came in well ahead of expectations, the analyst tells investors in a research note. The firm also believes J.H. Whitney's recently priced sale of 10M shares should begin to ease the stock's private equity and share liquidity overhang.
Truist
Hold
to
Hold
upgrade
2025-10-14
Reason
Truist
Price Target
2025-10-14
upgrade
Hold
to
Hold
Reason
Truist raised the firm's price target on Aveanna to $9.50 from $6.50 and keeps a Hold rating on the shares as part of a broader research note previewing Q3 results in Healthcare Service. The firm is "broadly bullish" on the industry as it expects ongoing strength in core demand drivers and continues to like the long-term positioning of covered names within their sector verticals, coupled with improved visibility around the regulatory environment, the analyst tells investors in a research note. Strong free cash flows and attractive financial flexibility across the bulk of the sector underpins the ongoing growth investment, Truist notes, adding that it sees a "brisk opportunity" to deploy capital to further augment core growth and drive M&A.
JPMorgan
Underweight -> Neutral
upgrade
$6 -> $10
2025-09-18
Reason
JPMorgan
Price Target
$6 -> $10
2025-09-18
upgrade
Underweight -> Neutral
Reason
JPMorgan upgraded Aveanna to Neutral from Underweight with a price target of $10, up from $6, after assuming coverage of the name. The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding. Aveanna's value proposition represents a "unique way" to gain exposure to the shift to home health, but if faces a challenging rate environment and broader reimbursement risk, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Aveanna Healthcare Holdings Inc (AVAH.O) is 15.65, compared to its 5-year average forward P/E of 40.13. For a more detailed relative valuation and DCF analysis to assess Aveanna Healthcare Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
40.13
Current PE
15.65
Overvalued PE
147.18
Undervalued PE
-66.92
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
12.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.19
Undervalued EV/EBITDA
10.77
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.41
Current PS
0.00
Overvalued PS
0.70
Undervalued PS
0.12
Financials
Annual
Quarterly
FY2025Q3
YoY :
+22.18%
621.94M
Total Revenue
FY2025Q3
YoY :
+53.36%
52.41M
Operating Profit
FY2025Q3
YoY :
-132.83%
14.06M
Net Income after Tax
FY2025Q3
YoY :
-127.27%
0.06
EPS - Diluted
FY2025Q3
YoY :
+14.72%
31.18M
Free Cash Flow
FY2025Q3
YoY :
+4.28%
32.19
Gross Profit Margin - %
FY2025Q3
YoY :
+620.00%
3.60
FCF Margin - %
FY2025Q3
YoY :
-126.84%
2.26
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 2356.91% over the last month.
Sold
0-3
Months
293.4M
USD
6
3-6
Months
11.9M
USD
6
6-9
Months
32.9M
USD
39
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 2356.91% over the last month.
Sold
0-3
Months
293.4M
USD
6
3-6
Months
11.9M
USD
6
6-9
Months
32.9M
USD
39
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AVAH News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
06:51:36
Aveanna increases FY25 revenue forecast to exceed $2.375B, up from over $2.3B
2025-11-06
06:49:52
Aveanna announces Q3 adjusted EPS of 15 cents, surpassing consensus estimate of 14 cents.
2025-10-22 (ET)
2025-10-22
10:00:03
Aveanna Experiences a 11.9% Decline
Sign Up For More Events
Sign Up For More Events
News
4.0
11-17Yahoo FinanceBMO Capital Begins Coverage of Aveanna Healthcare Holdings (AVAH) with a Buy Rating
4.0
11-11NASDAQ.COMDaily Upgrade Report for Validea's Joel Greenblatt Strategy - November 11, 2025
2.0
10-27NASDAQ.COMAveanna Healthcare (AVAH) Sees 13.99% Increase Over the Past Week: Key Insights to Consider
Sign Up For More News
People Also Watch
BFS
Saul Centers Inc
30.940
USD
+1.38%
UTL
Unitil Corp
49.040
USD
+0.06%
GRNT
Granite Ridge Resources Inc
5.120
USD
+3.02%
BXC
Bluelinx Holdings Inc
57.550
USD
+7.75%
UAN
CVR Partners LP
97.440
USD
+0.07%
REAX
Real Brokerage Inc
3.730
USD
+7.80%
COGT
Cogent Biosciences Inc
36.760
USD
+5.94%
NESR
National Energy Services Reunited Corp
13.790
USD
+2.99%
KRUS
Kura Sushi USA Inc
45.450
USD
+6.50%
AVO
Mission Produce Inc
11.540
USD
+0.26%
FAQ
What is Aveanna Healthcare Holdings Inc (AVAH) stock price today?
The current price of AVAH is 8.74 USD — it has increased 5.3 % in the last trading day.
What is Aveanna Healthcare Holdings Inc (AVAH)'s business?
What is the price predicton of AVAH Stock?
What is Aveanna Healthcare Holdings Inc (AVAH)'s revenue for the last quarter?
What is Aveanna Healthcare Holdings Inc (AVAH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aveanna Healthcare Holdings Inc (AVAH)'s fundamentals?
How many employees does Aveanna Healthcare Holdings Inc (AVAH). have?